-
South Africa approves emergency use of Coxing's new crown vaccine
Time of Update: 2021-08-16
On July 3, local time, the South African Health Products Regulatory Authority (SAHPRA) announced that it has approved the conditional emergency use of the new crown vaccine produced by China Kexing Company in South Africa .
-
13 injections are included!
Time of Update: 2021-08-16
▌ Winning rules and winning price▌ Winning rules and winning priceAccording to the announcement of the Jiangsu Medical Insurance Bureau, considering the attributes of drugs, the characteristics of clinical use in Jiangsu Province and the guarantee of supply, and according to the characteristics of different groups and market structure, the selected companies shall be determined by negotiation or bidding respectively: the total number of companies in Group A and Group B is different.
-
Top 50 global pharmaceutical companies and their best-selling drugs in 2021
Time of Update: 2021-08-16
The list is ranked based on the global sales revenue of prescription drugs of each pharmaceutical company in 2020, which more intuitively reflects the hard power of each company's pharmaceutical business .
This list focuses on the sales of prescription drugs by global pharmaceutical companies.
-
Aotai Biology, Kaitron Biology, and Oriental Biology win the case against gabapentin immunoassay product 337 investigation
Time of Update: 2021-08-16
"Science Innovation Board Daily" reported on the 3rd, on July 1, US time, the United States International Trade Commission (ITC) made a final ruling on the investigation of gabapentin immunoassay kit
-
Lansoprazole, ranitidine...another alliance starts drug procurement and reporting work
Time of Update: 2021-08-16
According to MRCLUB, on July 10, the Henan Provincial Medical Insurance Bureau announced the Henan-China Alliance’s "Notice on Filling in the Pre-purchasing Quantity of Drugs Procured in Centralized Purchases".
-
Tonghua Dongbao: Dongbao Zixing three-target inhibitor product obtained clinical approval
Time of Update: 2021-08-16
On June 28, Tonghua Dongbao announced that its three-target inhibitor product (THDBH101 capsule/WXSHC071 capsule) has been approved for clinical application.
As of the date of this announcement, the company has invested approximately RMB 25.
27 million in research and development expenses in this project .
-
Beida Pharmaceuticals BPI-23314 drug clinical trial application accepted
Time of Update: 2021-08-16
On the 29th, Betta Pharmaceuticals announced that it received the "Notice of Acceptance" issued by the NMPA, and the company declared BPI-23314 tablets for the treatment of malignant hematological tumors (including but not limited to myelofibrosis and other myeloproliferative tumors and myelodysplastic syndromes.
-
Hutchison Medicine initiates phase I clinical trials of a new ERK inhibitor HMPL-295 in China
Time of Update: 2021-08-16
After the initial dose escalation phase, an additional 10 to 15 patients will be included in the study and receive the recommended dose of phase II clinical study to further evaluate the safety and preliminary efficacy of HMPL-295 .
-
These "special" pharmacies cut prices by more than 50%
Time of Update: 2021-08-16
You can buy medicines that are reimbursed by medical insurance at a special outpatient pharmacy nearby .
In addition, 61 designated hospitals in Liuyang can also handle special outpatient services, realizing "dual-channel" purchase of medicines for outpatients of special diseases .
-
FDA releases Biogen Alzheimer's disease new drug review memorandum
Time of Update: 2021-08-16
Peter Stein, director of the Office of New Drugs, and the memorandum signed by Dr.
According to the data, CDER Director Patrizia Cavazzoni and Director of the Office of New Drugs Peter Stein both agreed with the accelerated approval proposed by Billy Dunn, head of FDA neuroscience, while the staff of the FDA Office of Biostatistics believed that approval was unnecessary .
-
"Eight provinces and two districts" inter-provincial alliance's procurement results officially announced!
Time of Update: 2021-08-16
On the 9th, the "Eight Provinces and Two Districts" Joint Procurement Office announced the official selection results of the "Eight Provinces and Two Districts" inter-provincial alliance drug centralized procurement (purchasing number: HLJ-YPDL2021-1), and the plan announced on June 24 The results of the selection are consistent, as follows:The "Eight Provinces and Two Districts" include Heilongjiang, Shanxi, Inner Mongolia Autonomous Region, Liaoning, Jilin, Sichuan, Tibet, Hainan, Qinghai, and Guizhou.
-
my country's first original ADC new drug Rongchang Biological Vidicuzumab is planned to be included in breakthrough therapy
Time of Update: 2021-08-16
On June 9th, the State Food and Drug Administration issued an announcement on the approval of the listing of vedicitumumab for injection, which is applicable to HER2 overexpression locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) that has received at least two systemic chemotherapy ) Treatment of patients .
-
Domestically produced inhalation agent Xiongqi has reduced the price by 80% to the original research!
Time of Update: 2021-08-16
Budesonide suspension for inhalation is the TOP1 terminal inhalation product in China's public medical institutions in 2020, with sales exceeding 5 billion yuan .
-
Hengrui Medicine: HRS3658 for injection was approved for clinical trial of drugs
Time of Update: 2021-08-16
On June 24, Hengrui Pharmaceuticals announced that its subsidiary product HRS3658 for injection has obtained a drug clinical trial approval notice, and the product is intended to be used for the treat
-
Pharmacopoeia Commission: Publicize 9 draft drug standards
Time of Update: 2021-08-16
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
Contact: Wang Zhijun; Zeng YiPhone: 010-67079559; 010-67079553Email: wangzhijun@chp.
-
Review of Ceftriaxone Sodium for Injection and Lansoprazole for Injection in Shanghai Pharmaceuticals
Time of Update: 2021-08-16
In May 2018, Shanghai Pharmaceutical Xinya submitted an application to the State Food and Drug Administration for the consistency evaluation of generic ceftriaxone sodium for injection and was accepted .
-
BeiGene tislelizumab's new indications for marketing applications are accepted in China
Time of Update: 2021-08-16
Today, BeiGene announced that the Center for Drug Evaluation (CDE) of the National Food and Drug Administration (NMPA) of China has accepted its anti-PD-1 antibody drug Bezean (tislelizumab injection) for the treatment of the past New indication marketing application (sBLA) for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed or become intolerable after receiving first-line standard chemotherapy .
-
Hisun Pharmaceutical's Class 1 new drug "Haibo Maibu Tablets" was approved for listing
Time of Update: 2021-08-16
For patients with atherosclerotic cardiovascular disease and other risk diseases, the target value has not reached the target value after conventional statin treatment In patients with hypercholesterolemia, on the basis of 10 mg atorvastatin as the background treatment, the dose of Hezemibu or atorvastatin was doubled, FAS set analysis, LDL-C Hezemibu was reduced by -16.
-
Amgen Carfilzomi is about to be approved in China
Time of Update: 2021-08-16
Carfilzomib (Kyprolis) is a proteasome inhibitor .
The proteasome can break down damaged or no longer needed proteins, and it plays an important role in the normal function and growth of cells .
-
The National Health Commission issued a notice on management indicators for the rational clinical application of anti-tumor drugs
Time of Update: 2021-08-16
On June 28, the National Health and Health Commission issued a message to guide medical institutions to scientifically set management indicators for the clinical application of anti-tumor drugs and improve the level of clinically reasonable application of anti-tumor drugs.
